| Income Statement | 2025-06-30 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenue | 209,082 | 232,933 | 225,991 | |
| Operating costs | 44,860 | 64,075 | 70,217 | |
| Restructuring charges | - | - | 239 | |
| Bad debt expense | - | 3 | 14 | |
| Medical costs | 146,410 | 182,693 | 177,681 | |
| Intangible assets impairment | 0 | - | 11,411 | |
| Depreciation and amortization | 3,555 | 3,504 | 3,978 | |
| Total operating expenses | 194,825 | 250,275 | 263,540 | |
| Operating income (loss) | 14,257 | -17,342 | -37,549 | |
| Interest expense | 6,878 | 5,413 | 4,110 | |
| Gain on troubled debt restructuring | 0 | - | - | |
| Warrant expense (income) | 562 | 459 | -2,213 | |
| Income (loss) from continuing operations before income taxes | 6,817 | -23,214 | -39,446 | |
| Income tax (benefit) expense | -21 | 2,793 | -187 | |
| Net income (loss) from continuing operations | 6,838 | -26,007 | -39,259 | |
| Loss from discontinued operations, net of tax | -8,386 | -14,358 | -18,439 | |
| Net loss | -1,548 | -40,365 | -57,698 | |
| Series a and b preferred stock dividend accrued | - | 10,667 | 10,422 | |
| Net income from continuing operations attributable to noncontrolling interests | 8,507 | 17,049 | 932 | |
| Series a and b preferred stock dividend accrued-Series BPreferred Stock | 2,465 | - | - | |
| Series a and b preferred stock dividend accrued-Series APreferred Stock | 10,981 | - | - | |
| Net loss attributable to neuehealth, inc. common shareholders | -23,501 | -70,475 | -71,390 | |
| Basic weighted-average common shares outstanding (in shares) | 8,978,000 | 8,282,000 | 8,253,000 | |
| Diluted weighted-average common shares outstanding (in shares) | 8,978,000 | 8,282,000 | 8,253,000 | |
| Net loss per share attributable to common stockholders, basic (in dollars per share) | -2.62 | -8.51 | -8.65 | |
| Net loss per share attributable to common stockholders, diluted (in dollars per share) | -2.62 | -8.51 | -8.65 | |
NeueHealth, Inc. (NEUE)
NeueHealth, Inc. (NEUE)